Ascidian Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ascidian Therapeutics, Inc. - overview
Established
2020
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Boston, US, and founded in 2020, Ascidian Therapeutics, created by ATP, is a biotech company that employs technologies to enable the therapeutic targeting of genes and genes with mutational diversity while preserving native gene expression patterns and levels to provide durability to gene therapy. In November 2023, Ascidian Therapeutics, Inc. raised USD 40 million in series A funding from returning investor Apple Tree Partners. As of October 2022, the firm is being led by Romesh Subramanian as its CEO.
The firm offers an RNA exon editing platform to create a novel RNA exon editor that offers a single exon editing molecule that can be used to replace several mutant exons via pre-mRNA trans-splicing, without changing DNA or introducing foreign enzymes to help reduce the risks associated with DNA editing and manipulation and has applications in ophthalmology, neurological and neuromuscular disorders, and other rare diseases. The company intends to use the October 2022 funding to modify the regulations of RNA splicing.
Current Investors
Apple Tree Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.ascidian-tx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.